Article information
Full text is only aviable in PDF
Bibliografía
[1.]
L.E. Gibson, R.E. Cooke.
A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis.
Pediatrics, 23 (1958), pp. 545-549
[2.]
B. Kerem, J.M. Rommens, J.A. Buchanan, D. Markiewicz, T.K. Cox, A. Chakravarti, et al.
Identification of the cystic fibrosis gene: genetic analysis.
Science, 245 (1989), pp. 1073-1080
[3.]
E.W. Alton, D. Currie, R. Logan-Sinclaur, J.O. Warner, M.E. Hodson, D.M. Geddes.
Nasal potential differen:ce: a clinical diagnostic test for cystic fibrosis.
Eur Respir J, 3 (1990), pp. 922-926
[4.]
B.J. Rosentein, G.R. Cutting.
The diagnosis of cystic fibrosis: a consensus statement.
J Pediatr, 132 (1998), pp. 589-599
[5.]
R.C. Stern.
The diagnosis of cystic fibrosis.
N Engl J Med, 336 (1997), pp. 487-491
[6.]
K.B. Hammond, N.L. Turcios, L.E. Gibson.
Clinical evaluation of the macrodut sweat test collection system and conductivity analyzer in the diagnosis of cystic fibrosis.
J Pediatr, 124 (1994), pp. 255-260
[7.]
C. Vázquez, M. Pérez de Saracho, L. Gastiasoro, J. Elorz.
Reevaluación 1996 del test del sudor y encuesta sobre su utilización en hospitales españoles.
An Esp Pediatr, (1996), pp. 61-62
[8.]
P.B. Davis, M. Drumm, M.W. Konstan.
Cystic fibrosis.
Am J Respir Crit Care Med, 154 (1996), pp. 1229-1256
[9.]
J. De Gracia, A. Álvarez, M. Vendrell, I. Hamad, D. Gallardo, N. Cobos, et al.
Genetic study in adult patients with cystic fibrosis.
Eur Respir J, 12 (1998), pp. 347-348
[10.]
X. Estivill.
Complexity in a monogenic disease.
Nature Genet, 12 (1996), pp. 348-350
[11.]
P. Lucas, R. Güell, V. Sobradillo, C.A. Jiménez, M. Sangenis, T. Montemayor, et al.
Normativa sobre la rehabilitación respiratoria.
Arch Bronconeumol, 36 (2000), pp. 257-274
[12.]
J. Thomas, D.J. Cook, D. Brooks.
Chest physical therapy management of patients with cystic fibrosis. A meta-analysis.
Am J Respir Crit Care Med, 151 (1995), pp. 846-850
[13.]
S.R. Boas.
Exercise recomendations for individuals with cystic fibrosis.
Sport Med, 24 (1997), pp. 17-37
[14.]
B.C. Marshall, W. Samuelson.
Basic therapies in cystic fibrosis. Does standard therapy work?.
Clin Chest Med, 19 (1998), pp. 487-504
[15.]
L. Varlotta, D.W. Schidlow.
CF lung disease: choosing an antibiotic regimen.
J Resp Dis, 18 (1997), pp. 414-422
[16.]
B.W. Ramsey.
Management of pulmonary disease in patients with cyctic fibrosis.
N Engl J Med, 335 (1996), pp. 179-188
[17.]
P.G. Noone, M.R. Knowles.
Standard therapy of cystic fibrosis lung disease.
Cystic fibrosis in adults, pp. 145-173
[18.]
J.D. Acton, J.M. Stark.
Management of acute exacerbations of cystic fibrosis lung disease.
Clin Pulm Med, 6 (1999), pp. 153-164
[19.]
L. Saiman, F. Mehar, W.W. Niu.
Antibiotic susceptibility testing of multiply resistant. Pseudomonas aeruginosa from patients with cystic fibrosis, including candidates for transplantation.
Clin Infect Dis, 23 (1996), pp. 532-537
[20.]
L. Máiz, C. Antelo, F. Baquero, N. Cobos, P. Morales, Pérez-Frías, et al.
Consenso sobre determinados aspectos de la patología pulmonar en pacientes con fibrosis quística.
Arch Bronconeumol, 35 (1999), pp. 339-344
[21.]
S. Mukdhopadhyay, M. Singh, J.I. Cater, S. Ogston, M. Franklin, R.E. Oliver.
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analisysis of benefits and risks.
Thorax, 51 (1996), pp. 364-373
[22.]
P.W. Campbell, L. Saimin.
Use of aerosolized antibiotics in patients with cystic fibrosis.
Chest, 116 (1999), pp. 775-788
[23.]
B.W. Ramsey, M.S. Pepe, J.M. Quan, K.L. Otto, A.B. Montgomery, J. Williams- Warren, et al.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.
N Engl J Med, 340 (1999), pp. 23-30
[24.]
J.L. Burns, J.M. Van Dalfsen, R.H. Shawar, K.L. Otto, R.L. Garber, J.M. Quan, et al.
Effect of chronic intermitent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
J Infect Dis, 179 (1999), pp. 1190-1196
[25.]
D.E. Geller.
Choosing a nebulizer for cystic fibrosis applications.
Curr Opin Pulm Med, 3 (1997), pp. 414-419
[26.]
Prober CG, Walson PD, Pharm D JJ, and the Committee on Infectious Disease and Committee on Drugs. Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics [serial online] 2000 Dec [citado 6 Dec 2000]. Disponible en: URL. http://www.peciatrics.org
[28.]
H.K. Johansen, T.A. Kovesi, C.h. Koch, M. Corey, N. Hoiby, H. Levison.
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen.
Pediatr Pulmonol, 26 (1998), pp. 89-96
[29.]
B. Frederiksen, C. Koch, N. Hoiby.
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Pediatr Pulmonol, 23 (1997), pp. 330-335
[30.]
J.S. Elborn, R.J. Prescott, B.H.R. Stack, M.C. Goodchild, J. Bates, C. Pantin, et al.
Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.
Thorax, 55 (2000), pp. 355-358
[31.]
K. McCaffery, R.E. Oliver, M. Franklin, S. Mukdopadhyay.
Systematic review of antistaphylococal antibiotic therapy in cystic fibrosis.
Thorax, 54 (1999), pp. 380-383
[32.]
H.J. Fuchs, D.S. Borowitz, D.H. Christiansen, E.M. Morris, M.L. Nah, B.W. Ramsey, et al.
for the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.
N Engl J Med, 331 (1994), pp. 637-642
[33.]
P.L. Shah, A. Bush, G.J. Canny, A.A. Colin, H.J. Fuchs, D.M. Geddes, et al.
Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short term, double-blind study followed by six months open-label treatment.
Eur Resp J, 8 (1995), pp. 954-958
[34.]
C.E. Kearney, C.E. Wallis.
Deoxyribonuclease for cystic fibrosis (Cochrane Review).
The Cochrane Library, Issue 4,
[35.]
N. Cobos, I. Danes, S. Gartner, M. González, S. Liñán, J.M. Aranau.
DNase use in the daily care of cystic fibrosis: who benefits from it and to what extend? Results of a cohort study of 199 patients in 13 centers. DNase National Study Group.
Eur J Pediatr, 159 (2000), pp. 176-181
[36.]
H. Eigen, B.J. Rosenstein, S. FitzSimmons, D.V. Schidlow, and the Cystic Fibrosis Foundation Prednisone Trial Group.
A multicenter suty of alternate-day prednisone therapy in patients with cystic fibrosis.
J Pediatr, 126 (1995), pp. 515-523
[37.]
K. Cheng, D. Ashby, R. Smyth.
Oral steroides for cystic fibrosis (Cochrane Review).
The Cochrane Library, Issue 4,
[38.]
W.H. Nikolaizik, M.H. Schoni.
Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis.
J Pediatr, 128 (1996), pp. 271-274
[39.]
M.W. Konstan, P.J. Byard, C.L. Hoppel, P.B. Davis.
Effect of highdose ibuprofen in patients with cystic fibrosis.
N Engl J Med, 332 (1995), pp. 848-854
[40.]
C.M. Oermann, M.M. Sockrider, M.W. Konstan.
The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes.
Chest, 115 (1999), pp. 1053-1058
[41.]
C. Dezateux, A. Crighton.
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis (Cochrane Review).
The Cochrane Library, Issue 4,
[42.]
P. Konig, J. Poehler, G.J. Barbero.
A placebo-controlled, doubleblind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.
Pediatr Pulmonol, 25 (1998), pp. 32-36
[43.]
J.R. Yankaskas, T.M. Egan, M.A. Mauro.
Major complications.
Cystic fibrosis in adults, pp. 175-193
[44.]
M.T. Martínez.
Complicaciones pulmonares no infecciosas en la fibrosis quística del adulto.
Arch Bronconeumol, 34 (1999), pp. 400-404
[45.]
C. Prados, L. Máiz, C. Antelo, F. Baranda, J. Blázquez, J.M. Borro, et al.
Fibrosis quística: consenso sobre el tratamiento del neumotórax y de la hemoptisis masiva y sobre las indicaciones del trasplante pulmonar.
Arch Bronconeumol, 36 (2000), pp. 411-416
[46.]
B.E. Noyes, D.M. Orenstein.
Treatment of pneumothorax in the era of transplantation for cystic fibrosis.
Chest, 101 (1992), pp. 1188-1197
[47.]
A. Wakabayashi, M. Brenner, A. Wilson, Y. Tadir, M. Berns.
Thoracoscopic treatment of spontaneous pneumothorax using carbon dioxide laser.
Ann Thorac Surg, 50 (1990), pp. 786-790
[48.]
M. Noppen, E. Dhondt, T. Mahler, A. Malfroot, I. Dab, W. Vincken.
Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage.
Chest, 106 (1994), pp. 262-264
[49.]
SEPAR Grupo de Trabajo de la.
Normativa sobre el manejo de la hemoptisis amenazante.
Arch Bronconeumol, 33 (1997), pp. 31-40
[50.]
P.H. Sammut, L.M. Taussing.
Complications of respiratory disease and their management. Cystic fibrosis in adolescent and adult.
pp. 377-427
[51.]
G. Mastella, M. Rainisio, H.K. Harms, M.E. Hodson, C. Koch, J. Navarro, et al.
on behalf of investigators of the Epidemiologic Registry of Cystic Fibrosis. Allergic broncopulmonary aspergillosis in cistic fibrosis. A European epidemiological study.
Eur Respir J, 16 (2000), pp. 464-471
[52.]
R. Patterson, P.A. Greenberger, R.C. Radin, M. Roberts.
Allergic bronchopulmonary aspergillosis: staging as an aid to management.
Ann Intern Med, 96 (1982), pp. 286-291
[53.]
P.S. Hutcheson, A.J. Regent, R.G. Slavin.
Variability in immune parameters of allergic bronchopulmnary aspergillosis in patient with cystic fibrosis.
J Allergy Clin Immunol, 88 (1991), pp. 390-394
[54.]
I.B. Nepomuceno, S. Esrig, R.B. Moss.
Allergic bronchopulmonary aspergillosis in cystic fibrosis. Role of atopy and response to itraconazole.
Chest, 115 (1999), pp. 364-370
[55.]
D.A. Stevens, H.J. Schwartz, J.Y. Lee, B.L. Moskowitz, D.C. Jerome, A. Catanzaro, et al.
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.
N Engl J Med, 342 (2000), pp. 756-762
[56.]
J.R. Yankaskas, G.B. Mallory.
and the Consensus Committee. Lung transplantation in cystic fibrosis consensus conference statement.
Chest, 113 (1998), pp. 217-226
[57.]
M.J. Wells, A.E. Smith.
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.
Cell, 73 (1993), pp. 1251-1254
[58.]
M. Drumm.
What happens to DF508 in vivo?.
J Clin Invest, 103 (1999), pp. 1369-1370
[59.]
R.C. Rubenstein, P.L. Zeitlin.
A pilot clinical trial of sodium 4- phenybutyrate (buphenyl) in DF508-homozygous cystic fibrosis patients: evidence of restoration of nasal epithelial CFTR function.
Am J Respir Crit Care Med, 157 (1998), pp. 484-490
Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica
